Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course - PubMed (original) (raw)
Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course
Mohsen Khademi et al. Mult Scler. 2011 Mar.
Abstract
Background: Levels of CXCL13, a potent B-cell chemoattractant, are elevated in the cerebrospinal fluid (CSF) during multiple sclerosis (MS) and are associated with markers of MS activity. Levels decrease upon effective treatments.
Objective: Here we validate the potential role of CSF CXCL13 as a biomarker for aspects of MS in a large amount of clinical material, the majority collected at early diagnostic work-up.
Methods: CXCL13 was measured by ELISA in 837 subjects: relapsing-remitting MS (RRMS; n=323), secondary progressive MS (SPMS; n=40), primary progressive MS (PPMS; n=24), clinically isolated syndrome (CIS; n=79), other neurological diseases (ONDs; n=181), ONDs with signs of inflammation or viral/bacterial infections (iONDs; n=176) and healthy controls (n=14).
Results: Subjects with viral/bacterial infections had extremely high CXCL13 levels compared to all included groups (p<0.0001). CXCL13 was otherwise significantly higher in MS compared to the remaining controls (p<0.0001), and CIS (p<0.01). A significant and positive correlation between CXCL13 and relapse rate, the results obtained for the Expanded Disability Status Scale (EDSS) and the number of lesions detected by MRI was demonstrated. CXCL13 was increased in CIS conversion to clinically definite MS (p<0.001). Oligoclonal immunoglobulin band (OCB)-positive CIS or MS had significantly increased CXCL13 levels compared to OCB-negative CIS or MS (p<0.001 and p<0.0001, respectively).
Conclusion: CXCL13 was associated with disease exacerbations and unfavourable prognosis in RRMS. Increased CXCL13 was not specific for MS since subjects with viral/bacterial infections exhibited even higher levels. High levels predicted CIS conversion to MS. We suggest that measurement of CSF CXCL13 can be part of the armamentarium in the diagnostic and prognostic work-up in MS and be of help in future treatment decisions.
Similar articles
- Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM.
Sola P, Mandrioli J, Simone AM, Ferraro D, Bedin R, Annecca R, Venneri MG, Nichelli PF, Merelli E. Sola P, et al. Mult Scler. 2011 Mar;17(3):303-11. doi: 10.1177/1352458510386996. Epub 2010 Nov 15. Mult Scler. 2011. PMID: 21078694 - Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis.
Börnsen L, Khademi M, Olsson T, Sørensen PS, Sellebjerg F. Börnsen L, et al. Mult Scler. 2011 Jan;17(1):32-42. doi: 10.1177/1352458510382247. Epub 2010 Oct 4. Mult Scler. 2011. PMID: 20921238 - Cannabinoids and B cells: emerging targets for treating progressive multiple sclerosis.
Giovannoni G. Giovannoni G. Mult Scler. 2011 Mar;17(3):259-61. doi: 10.1177/1352458511399799. Mult Scler. 2011. PMID: 21362756 No abstract available. - The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review.
Karussis D. Karussis D. J Autoimmun. 2014 Feb-Mar;48-49:134-42. doi: 10.1016/j.jaut.2014.01.022. Epub 2014 Feb 10. J Autoimmun. 2014. PMID: 24524923 Review. - [Relapsing-remitting inflammatory disease of the central nervous system with normal MRI: multiple sclerosis or phenocopy in a series of 15 patients].
Lebrun C, Bourg V, Chanalet S, Chatel M. Lebrun C, et al. Rev Neurol (Paris). 2003 Apr;159(4):397-404. Rev Neurol (Paris). 2003. PMID: 12773868 Review. French.
Cited by
- Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel.
Stilund M, Gjelstrup MC, Petersen T, Møller HJ, Rasmussen PV, Christensen T. Stilund M, et al. PLoS One. 2015 Apr 10;10(4):e0119681. doi: 10.1371/journal.pone.0119681. eCollection 2015. PLoS One. 2015. PMID: 25860354 Free PMC article. - The evidence for a role of B cells in multiple sclerosis.
Disanto G, Morahan JM, Barnett MH, Giovannoni G, Ramagopalan SV. Disanto G, et al. Neurology. 2012 Mar 13;78(11):823-32. doi: 10.1212/WNL.0b013e318249f6f0. Neurology. 2012. PMID: 22411958 Free PMC article. Review. - Serum Levels of CXCL13 Are Associated With Teriflunomide Response in Patients With Multiple Sclerosis.
Fissolo N, Pappolla A, Rio J, Villar LM, Perez-Hoyos S, Sanchez A, Gutierrez L, Montalban X, Comabella M. Fissolo N, et al. Neurol Neuroimmunol Neuroinflamm. 2022 Nov 21;10(1):e200050. doi: 10.1212/NXI.0000000000200050. Print 2023 Jan. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 36411079 Free PMC article. - B cells and antibodies in multiple sclerosis pathogenesis and therapy.
Krumbholz M, Derfuss T, Hohlfeld R, Meinl E. Krumbholz M, et al. Nat Rev Neurol. 2012 Nov 5;8(11):613-23. doi: 10.1038/nrneurol.2012.203. Epub 2012 Oct 9. Nat Rev Neurol. 2012. PMID: 23045237 Review. - The Brave New World of Early Treatment of Multiple Sclerosis: Using the Molecular Biomarkers CXCL13 and Neurofilament Light to Optimize Immunotherapy.
Pachner A. Pachner A. Biomedicines. 2022 Aug 28;10(9):2099. doi: 10.3390/biomedicines10092099. Biomedicines. 2022. PMID: 36140203 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources